{{medical}}
{{drugbox
| Verifiedfields = changed
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 4RKY41TBTF
| verifiedrevid = 400836032
|
|IUPAC_name = (2''R'',3''R'')-3,5,7-trihydroxy-<br />2-[(2''R'',3''R'')-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)<br />-2,3-dihydrobenzo[''b''][1,4]dioxin-6-yl]chroman-4-one
| image = Silibinin skeletal.svg
| image2 = Silibinin 3D.png
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 29263
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 9509
| InChI = 1/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3/t20-,23+,24-,25-/m1/s1
| InChIKey = SEBFKMXJBCUCAI-HKTJVKLFBV
| smiles = O=C4c5c(O)cc(O)cc5O[C@H](c2ccc1O[C@@H]([C@H](Oc1c2)c3ccc(O)c(OC)c3)CO)[C@H]4O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3/t20-,23+,24-,25-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = SEBFKMXJBCUCAI-HKTJVKLFSA-N
| InChI1 = 1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3/t20-,23+,24-,25-/m1/s1
| InChIKey1 = SEBFKMXJBCUCAI-HKTJVKLFSA-N
| CAS_number= 65666-07-1
| CAS_number_Ref= {{cascite|changed|??}}
| CAS_number2= 22888-70-6
| CAS_number2_Ref= {{cascite|changed|??}}
| ATC_prefix=A05
| ATC_suffix=BA03
| PubChem= 31553
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank=
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D08515
| C = 25 |H = 22 |O = 10
| molecular_weight = 482.44 g/mol
| bioavailability=
| metabolism =
| elimination_half-life=
| excretion =
| pregnancy_category =
| legal_status =
| routes_of_administration= 
}}
'''水飛薊素'''（英語：'''Silibinin''' (INN)）是種抗氧化劑和藥物，從一種名為[[乳薊|乳薊]]（Milk Thistle）的植物提煉而成，是該植物的主要活性成分之一。本藥獲批准用於治療肝中毒、[[肝炎|慢性肝炎]]及[[肝硬化|肝硬化]]，但其效用尚未完全確立。'''Silymarin'''是[[乳薊|乳薊]]的一种标准提取物，其主要成分除了水飛薊素外还有几种{{tsl|en|Flavonolignan|黄酮木酚}}。

==藥理學和毒理學==
儘管水飛薊素擁有多個[[羥基|羥基]]，其水溶性並不高。'''Silipide'''（商品名 '''Siliphos'''）是[[磷脂酰胆碱|磷脂酰胆碱]]和水飛薊素的[[超分子|超分子化合物]]，其[[生物利用度|生物利用度]]大為提升。兩個研究分別指出，相比未經修飾的水飛薊素，Silipide的生物利用度要高出4.6倍<ref>{{cite journal | vauthors = Barzaghi N, Crema F, Gatti G, Pifferi G, Perucca E | year = 1990 | title =  Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects| pmid = 2088770| journal = Eur J Drug Metab Pharmacokinet | volume = 15 | issue = | pages = 333–8 | doi=10.1007/bf03190223}}</ref>和10倍<ref name=Kidd2005/>。除此以外，文獻報導，水飛薊素和[[环糊精|β環糊精]]的超分子化合物水溶性也有顯著改善<ref name=Voinovich2009/>，而水飛薊素的[[糖苷|糖苷]]則具備更高的水溶性和更強的肝臟保護作用<ref name=Kosina2002/>。

作為一種[[黄酮类化合物|黄酮类化合物]]，水飛薊素可抑制{{le|P-糖蛋白|P-glycoprotein}}輔助的細胞外流<ref group="註">注意，不是[[胞吐作用|胞吐作用]]。</ref><ref name=Zhou2004/>。由於許多藥物是P-糖蛋白的[[底物|底物]]，對P-糖蛋白的調節作用或會改變其他藥物的吸收和生物利用度。再者，水飛薊素可抑制[[細胞色素P450|細胞色素P450酶]]，故水飛薊素很可能和大多數藥物存在[[药物相互作用|药物相互作用]]<ref name=Wu2009/>。

在晚期[[前列腺癌|前列腺癌]]病人進行的第一期臨床研究指出，每日高達13克劑量的水飛薊素耐受性良好。最常見的副作用為無徵狀的肝功能異常，例如[[膽紅素|膽紅素]]和[[谷丙转氨酶|谷丙转氨酶]]升高<ref>{{cite journal | journal = Investigational New Drugs | year = 2007 | volume = 25 | issue = 2 | pages = 139–146 | title = A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients |author1=Thomas W. Flaig |author2=Daniel L. Gustafson |author3=Lih-Jen Su |author4=Joseph A. Zirrolli |author5=Frances Crighton |author6=Gail S. Harrison |author7=A. Scott Pierson |author8=Rajesh Agarwal |author9=L. Michael Glodé | doi=10.1007/s10637-006-9019-2}}</ref>。動物模型之中未曾偵測出任何的胚胎毒性<ref name=Fraschini2002/><ref name=Hahn1968/>。

==醫學用途==
[[考科藍|考科藍]]於2007年的系統綜述指出，基於18個臨床研究和1088名[[肝炎#酒精性|酒精性]]及/或[[病毒性肝炎|病毒性肝炎]]（乙型、丙形）病人的數據，利用水飛薊來治療這些病人的好處值得商榷，而且缺乏高品質的證據來支持這種療法。綜述認為需要進行更多高品質[[隨機|隨機]][[對照實驗|對照]][[臨床研究|臨床研究]]才可得出結論<ref>{{cite journal |vauthors=Rambaldi A, Jacobs BP, Gluud C |title=Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases |journal=The Cochrane Database of Systematic Reviews |volume= |issue=4 |pages=CD003620 |year=2007 |pmid=17943794 |doi=10.1002/14651858.CD003620.pub3}}</ref>。研究人員正探討水飛薊素在治療癌症方面的應用，這是因為水飛薊素能壓抑[[STAT3|STAT3]]的信號傳導和干擾其他的生物化學過程<ref>{{cite journal |vauthors=Bosch-Barrera J, Menendez JA |title=Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy |journal=Cancer Treat. Rev. |volume=41 |issue=6 |pages=540–6 |year=2015 |pmid=25944486 |doi=10.1016/j.ctrv.2015.04.008 |type=Review}}</ref>。根據{{link-en | 英国癌症研究中心 |Cancer Research UK}}，互聯網上出現不少聲稱水飛薊能減緩某些癌症的宣傳信息，但這些講法目前仍未有足夠證據支持<ref>{{cite web |publisher=Cancer Research UK |accessdate=March 2015 |title=Milk thistle and liver cancer |date=2015-03-08 |url=http://www.cancerresearchuk.org/about-cancer/cancers-in-general/cancer-questions/milk-thistle-and-liver-cancer |archive-date=2017-02-15 |archive-url=https://web.archive.org/web/20170215144158/http://www.cancerresearchuk.org/about-cancer/cancers-in-general/cancer-questions/milk-thistle-and-liver-cancer |dead-url=no }}</ref>。

在某些歐洲國家，水飛薊素是種臨床用藥，商品名為Legalon和Silimarit，可用作治療肝中毒（例如[[毒鵝膏|毒鵝膏]]中毒）和慢性[[肝炎|肝炎]]及[[肝硬化|肝硬化]]的輔助治療。這些製劑是水飛薊素在2'和3'位置[[酯化|酯化]]嫁接雙氫[[琥珀酸|琥珀酸]]後中和所得的鈉鹽，水溶性良好，適合經口服以外的途徑<ref group="註">例如靜脈注射、肌肉注射。</ref>給藥。2011年，歐盟給予Legalon罕見病藥用品待遇，適應症為防止肝臟移植者受[[丙型肝炎|丙型肝炎]]復發所害<ref>Rottapharm|Madaus. [http://www.rotta.com/en/service/media/comunicatiStampa/pdf/legalon_ENG.pdf Media Communications Legalon®] {{Wayback|url=http://www.rotta.com/en/service/media/comunicatiStampa/pdf/legalon_ENG.pdf |date=20121115020715 }}. Retrieved March 6 2017.</ref>。

皮膚護理方面，水飛薊素具備多重功效，包括保護肌膚免受環境毒素侵害、抗發炎功效、抑制紫外線引起的{{le|表皮增生|Hyperplasia}}和[[皮膚癌|皮膚癌]]、預防[[曬傷|曬傷]]、以及促進修復紫外線引起的[[DNA修復#DNA损伤|DNA損傷]]<ref>{{cite journal|last1=Singh|first1=Rana P.|last2=Agarwal|first2=Rajesh|title=Cosmeceuticals and silibinin|journal=Clinics in Dermatology|date=September 2009|volume=27|issue=5|pages=479–484|doi=10.1016/j.clindermatol.2009.05.012|pmid=19695480|pmc=2767273}}</ref>。

水飛薊素可透過利用[[水飛薊|水飛薊]]的{{le|傷癒組織|Callus (cell biology)}}或細胞懸浮液進行[[植物組織培養|植物組織培養]]大量製取，[[吡嗪酰胺|吡嗪酰胺]]的衍生物可誘導水飛薊細胞合成包括水飛薊素在內的[[黃酮醇|黃酮醇]]-[[木質素|木質素]]加成物<ref>{{cite journal | vauthors = Tůmová L, Tůma J, Megušar K, Doleža M | year = 2010 | title = Substituted Pyrazinecarboxamides as Abiotic Elicitors of Flavolignan Production in Silybum marianum (L.) Gaertn Cultures in Vitro | url = | journal = Molecules | volume = 15 | issue = 1| pages = 331–340 | doi = 10.3390/molecules15010331 }}</ref>。

==備註==
<references group="註" />

==參考資料==
{{Reflist|30em|refs=
<ref name=Kidd2005>{{cite journal |vauthors=Kidd P, Head K |title=A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos) |journal=Alternative Medicine Review |volume=10 |issue=3 |pages=193–203 |year=2005 |pmid=16164374 |doi= |url=http://www.altmedrev.com/publications/10/3/193.pdf |accessdate=2010-12-14 |archive-date=2017-08-09 |archive-url=https://web.archive.org/web/20170809134407/http://altmedrev.com/publications/10/3/193.pdf |dead-url=no }}</ref>

<ref name=Kosina2002>{{cite journal |vauthors=Kosina P, Kren V, Gebhardt R, Grambal F, Ulrichová J, Walterová D |title=Antioxidant properties of silybin glycosides |journal=Phytotherapy Research : PTR |volume=16 Suppl 1 |issue= |pages=S33–9 |year=2002  |pmid=11933137 |doi= 10.1002/ptr.796}}</ref>

<ref name=Voinovich2009>{{cite journal |vauthors=Voinovich D, Perissutti B, Grassi M, Passerini N, Bigotto A |title=Solid state mechanochemical activation of ''Silybum marianum'' dry extract with betacyclodextrins: Characterization and bioavailability of the coground systems |journal=Journal of Pharmaceutical Sciences |volume=98 |issue=11 |pages=4119–29 |year=2009 |pmid=19226635 |doi=10.1002/jps.21704}}</ref>

<ref name=Wu2009>{{cite journal |vauthors=Wu JW, Lin LC, Tsai TH |title=Drug-drug interactions of silymarin on the perspective of pharmacokinetics |journal=Journal of Ethnopharmacology |volume=121 |issue=2 |pages=185–93 |year=2009 |pmid=19041708 |doi=10.1016/j.jep.2008.10.036 |url=http://linkinghub.elsevier.com/retrieve/pii/S0378-8741(08)00621-1 |accessdate=2010-12-14 |archive-date=2020-07-22 |archive-url=https://web.archive.org/web/20200722100511/https://www.sciencedirect.com/science/article/abs/pii/S0378874108006211?via%3Dihub |dead-url=no }}</ref>

<ref name=Zhou2004>{{cite journal |vauthors=Zhou S, Lim LY, Chowbay B |title=Herbal modulation of P-glycoprotein |journal=Drug Metabolism Reviews |volume=36 |issue=1 |pages=57–104 |year=2004 |pmid=15072439 |doi=10.1081/DMR-120028427 |url=http://www.informapharmascience.com/doi/abs/10.1081/DMR-120028427 |deadurl=yes |archiveurl=https://web.archive.org/web/20160303234202/http://www.informapharmascience.com/doi/abs/10.1081/DMR-120028427 |archivedate=2016-03-03 }}</ref>

<ref name=Fraschini2002>{{cite journal |vauthors=Fraschini F, Demartini G, Esposti D |title=Pharmacology of Silymarin |journal=Clinical Drug Investigation |volume=22 |issue=1 |pages=51–65 |year=2002 |doi=10.2165/00044011-200222010-00007 |url=http://adisonline.com/druginvestigation/Abstract/2002/22010/Pharmacology_of_Silymarin.7.aspx |deadurl=yes |archiveurl=https://archive.is/20130116072905/http://adisonline.com/druginvestigation/Abstract/2002/22010/Pharmacology_of_Silymarin.7.aspx |archivedate=2013年1月16日 |df= }}</ref>

<ref name=Hahn1968>{{cite journal |vauthors=Hahn G, Lehmann HD, Kürten M, Uebel H, Vogel G |title=On the pharmacology and toxicology of silymarin, an antihepatotoxic active principle from Silybum marianum (L.) gaertn |journal=Arzneimittelforschung |volume=18 |issue=6 |pages=698–704 |year=1968 |pmid=5755807 }}</ref>
}}

==延伸閱讀==
* [http://www.mayoclinic.com/health/silymarin/NS_patient-milkthistle 马约诊所對於水飛薊的藥用功效的證據質量所作的文獻回顧] {{Wayback|url=http://www.mayoclinic.com/health/silymarin/NS_patient-milkthistle |date=20080203120301 }}
*{{cite journal |vauthors=Morazzoni P, Bombardelli E |title=''Silybum marianum'' (cardus marianus) |journal=Fitoterapia |volume=66 |pages=3–42 |year=1994}}
*{{cite journal |vauthors=Saller R, Meier R, Brignoli R |title=The use of silymarin in the treatment of liver diseases |journal={{le|藥物期刊|Drugs (journal)}} |volume=61 |issue=14 |pages=2035–63 |year=2001 |pmid=11735632 |doi=10.2165/00003495-200161140-00003 }}

{{肝、胆疾病治疗药}}

[[Category:植物化學成分|Category:植物化學成分]]
[[Category:解毒剂|Category:解毒剂]]
[[Category:抗氧化剂|Category:抗氧化剂]]
[[Category:抗肿瘤药|Category:抗肿瘤药]]
[[Category:黄酮木脂素|Category:黄酮木脂素]]
[[Category:天然酚类药物|Category:天然酚类药物]]
[[Category:苯醚|Category:苯醚]]
[[Category:间苯二酚|Category:间苯二酚]]
[[Category:苯并二氧芑|Category:苯并二氧芑]]
[[Category:芳族酮|Category:芳族酮]]
[[Category:二噁烷|Category:二噁烷]]